IL252796B - Therapeutic, diagnostic and prognostic methods for bladder cancer - Google Patents

Therapeutic, diagnostic and prognostic methods for bladder cancer

Info

Publication number
IL252796B
IL252796B IL252796A IL25279617A IL252796B IL 252796 B IL252796 B IL 252796B IL 252796 A IL252796 A IL 252796A IL 25279617 A IL25279617 A IL 25279617A IL 252796 B IL252796 B IL 252796B
Authority
IL
Israel
Prior art keywords
diagnostic
therapeutic
bladder cancer
prognostic methods
prognostic
Prior art date
Application number
IL252796A
Other languages
Hebrew (he)
Other versions
IL252796A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL252796A0 publication Critical patent/IL252796A0/en
Publication of IL252796B publication Critical patent/IL252796B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL252796A 2014-12-24 2017-06-08 Therapeutic, diagnostic and prognostic methods for bladder cancer IL252796B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096741P 2014-12-24 2014-12-24
PCT/US2015/000237 WO2016105503A1 (en) 2014-12-24 2015-12-23 Therapeutic, diagnostic and prognostic methods for cancer of the bladder

Publications (2)

Publication Number Publication Date
IL252796A0 IL252796A0 (en) 2017-08-31
IL252796B true IL252796B (en) 2022-04-01

Family

ID=55275150

Family Applications (1)

Application Number Title Priority Date Filing Date
IL252796A IL252796B (en) 2014-12-24 2017-06-08 Therapeutic, diagnostic and prognostic methods for bladder cancer

Country Status (14)

Country Link
US (3) US20170306418A1 (en)
EP (2) EP3237638B1 (en)
JP (2) JP6900314B2 (en)
KR (1) KR20170095893A (en)
CN (1) CN107223163A (en)
AU (1) AU2015371312B2 (en)
CA (1) CA2969830A1 (en)
HK (1) HK1244847A1 (en)
IL (1) IL252796B (en)
MX (1) MX394474B (en)
MY (1) MY188938A (en)
RU (1) RU2739942C2 (en)
SG (1) SG11201704852SA (en)
WO (1) WO2016105503A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
PT3434767T (en) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
CN104039342A (en) 2011-10-18 2014-09-10 爱勒让治疗公司 peptidomimetic macrocycle
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
MX389354B (en) 2014-09-24 2025-03-20 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF.
MX2017003797A (en) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof.
JP2017538708A (en) * 2014-12-11 2017-12-28 バイエル・ファルマ・アクティエンゲゼルシャフト Use of pan FGFR inhibitors and methods for identifying patients with cancer eligible for treatment with pan FGFR inhibitors
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
US20180165599A1 (en) * 2016-12-12 2018-06-14 Business Objects Software Ltd. Predictive model integration
EP3682238A4 (en) * 2017-09-14 2020-12-16 Siemens Healthcare Diagnostics Inc. ADHESIVE POLYMER WITH MEMBRANES FOR IN VITRO DIAGNOSTIC DEVICES
CN110115758B (en) * 2018-02-05 2021-05-11 中山大学 Application of PIK3IP1 protein in regulating T cell response and preparing anti-tumor medicine
CN108676884A (en) * 2018-06-04 2018-10-19 海口市人民医院（中南大学湘雅医学院附属海口医院） Tumor marker for predicting bladder cancer
CN112955747A (en) * 2018-09-19 2021-06-11 豪夫迈·罗氏有限公司 Methods for treatment and diagnosis of bladder cancer
CN111289748A (en) * 2018-12-08 2020-06-16 惠州市中大惠亚医院 Application of ErbB3 protein in preparation of bladder cancer noninvasive diagnosis product
JP2022515198A (en) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolo [1,5-a] pyridine compound as an inhibitor of FGFR tyrosine kinase
CN113474337A (en) 2018-12-19 2021-10-01 奥瑞生物药品公司 7- ((3, 5-dimethoxyphenyl) amino) quinoxaline derivatives as FGFR inhibitors for the treatment of cancer
JP7721449B2 (en) * 2019-04-12 2025-08-12 ストラティファイヤー・モレキュラー・パソロジー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Methods for classifying samples based on FGFR determinations
CN110055331B (en) * 2019-05-10 2023-05-02 人和未来生物科技（长沙）有限公司 Kit for bladder cancer auxiliary diagnosis or screening and application thereof
JPWO2021010326A1 (en) * 2019-07-12 2021-01-21
US20230115945A1 (en) 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Aminopyrimidine compounds
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
CN111269983A (en) * 2020-02-21 2020-06-12 深圳市众循精准医学研究院 FISH detection method, probe and kit for bladder cancer gene amplification
EP4121565A4 (en) * 2020-03-18 2024-12-11 The Regents of University of California RISK STRATIFICATION OF PATIENTS WITH MENINGIOMA
CN111679076A (en) * 2020-06-15 2020-09-18 吉林医药学院 A detection kit for detecting cyclinD1 and BCL-2 antibodies
US20230178177A1 (en) * 2020-06-30 2023-06-08 Northwestern University A single patient classifier for t1 high grade bladder cancer
GB2597332A (en) * 2020-07-20 2022-01-26 Institute Of Cancer Res Prognostic and treatment response predictive method
MX2023007793A (en) 2020-12-30 2023-09-22 Tyra Biosciences Inc Indazole compounds as kinase inhibitors.
WO2022174234A2 (en) * 2021-02-10 2022-08-18 Foundation Medicine, Inc. Biomarkers for cancer treatment
MX2023009954A (en) 2021-02-26 2023-11-09 Tyra Biosciences Inc Aminopyrimidine compounds and methods of their use.
JP2023023327A (en) * 2021-08-05 2023-02-16 国立大学法人大阪大学 Methods for determining tumor subtypes and application thereof, and methods of subtype determination
IT202200001817A1 (en) 2022-02-02 2023-08-02 Aizoon S R L Procedure for the prognosis of a disease following a therapeutic treatment, related system and IT product
IT202200005861A1 (en) 2022-03-24 2023-09-24 Aizoon S R L PROCEDURE TO ESTIMATE A VARIABLE OF INTEREST ASSOCIATED WITH A GIVEN DISEASE AS A FUNCTION OF A PLURALITY OF DIFFERENT OMICS DATA, RELATED DEVICE AND COMPUTER PRODUCT
CN115343474B (en) * 2022-06-27 2024-12-27 陕西佰美基因股份有限公司 Applications, products, expression interference reagents and prognostic model construction methods of CKAP4 protein
TW202416961A (en) 2022-06-29 2024-05-01 美商泰拉生物科學公司 Indazole compounds
EP4547670A1 (en) 2022-06-29 2025-05-07 Tyra Biosciences, Inc. Polymorphic compounds and uses thereof
AU2023208071A1 (en) 2022-07-25 2024-02-08 Aizoon S.r.l. Method for providing a clinical decision support, corresponding system for providing a clinical decision support, and computer program product
WO2024138112A1 (en) 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
WO2025129014A1 (en) 2023-12-15 2025-06-19 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer
WO2025222097A1 (en) 2024-04-19 2025-10-23 Tyra Biosciences, Inc. Indazole-based protac degraders and their anticancer activity
WO2026035809A1 (en) 2024-08-06 2026-02-12 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5527676A (en) 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
EP0672035A1 (en) 1993-10-01 1995-09-20 Novartis AG Pyrimidineamine derivatives and processes for the preparation thereof
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
EP0682027B1 (en) 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidine derivatives with antiproliferative action
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
DE69522717T2 (en) 1995-03-30 2002-02-14 Pfizer Inc., New York quinazoline derivatives
AU711592B2 (en) 1995-04-03 1999-10-14 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
ATE212993T1 (en) 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh PYROLOPYRIMIDINES AND METHOD FOR THE PRODUCTION THEREOF
DK9500262U4 (en) 1995-07-07 1996-10-07 Bonus Energy As Bottom frame for wind turbine housing and wind turbine comprising the same
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AR004010A1 (en) 1995-10-11 1998-09-30 Glaxo Group Ltd HETERO CYCLIC COMPOUNDS
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6140317A (en) 1996-01-23 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
JP3406763B2 (en) 1996-01-30 2003-05-12 東レ・ダウコーニング・シリコーン株式会社 Silicone rubber composition
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19608588A1 (en) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and processes for their preparation
DE19629652A1 (en) 1996-03-06 1998-01-29 Thomae Gmbh Dr K 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation
AU716383B2 (en) 1996-03-15 2000-02-24 Novartis Ag Novel N-7-heterocyclyl pyrrolo(2,3-d)pyrimidines and the use thereof
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
DE69734513T2 (en) 1996-06-24 2006-07-27 Pfizer Inc. PHENYLAMINO-SUBSTITUTED TRICYCL DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
ES2191187T3 (en) 1996-07-13 2003-09-01 Glaxo Group Ltd BICYCLE HETEROAROMATIC COMPOUNDS AS INHIBITORS OF PROTEIN TIROSIN-QUINASA.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
JP4386967B2 (en) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド Condensed heterocyclic compounds as protein tyrosine kinase inhibitors
DE69738468T2 (en) 1996-08-23 2009-01-08 Novartis Ag SUBSTITUTED PYRROLOPYRIMIDINES AND METHOD FOR THE PRODUCTION THEREOF
WO1998014449A1 (en) 1996-10-02 1998-04-09 Novartis Ag Fused pyrazole derivatives and processes for their preparation
ID18494A (en) 1996-10-02 1998-04-16 Novartis Ag PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT
WO1998014450A1 (en) 1996-10-02 1998-04-09 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
DE69839338T2 (en) 1997-02-05 2008-07-10 Warner-Lambert Company Llc PYRIDO (2,3-D) PYRIMIDINE AND 4-AMINO-PYRIMIDINE AS INHIBITORS OF CELLULAR PROLIFERATION
WO1999007701A1 (en) 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
US6291496B1 (en) * 1999-12-27 2001-09-18 Andrew J. Dannenberg Treating cancers associated with overexpression of class I family of receptor tyrosine kinases
JP2003529774A (en) 2000-03-31 2003-10-07 ジェネンテック・インコーポレーテッド Compositions and methods for detecting and quantifying gene expression
US6500633B1 (en) * 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
JP4731793B2 (en) 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド Crystals of whole antibodies or fragments thereof, and methods for making and using the crystals
US20060008823A1 (en) 2004-05-12 2006-01-12 Kemp Jennifer T DNA profiling and SNP detection utilizing microarrays
ES2564127T5 (en) * 2004-06-04 2020-03-26 Genentech Inc EGFR mutations
EP3702371B1 (en) 2009-03-25 2022-11-02 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
US20130059303A1 (en) * 2011-09-06 2013-03-07 Francois Radvanyi Cdkn2a as a prognostic marker in bladder cancer
WO2014018841A1 (en) 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
US20150293105A1 (en) * 2012-10-26 2015-10-15 The University Of Queensland Methods for classifying tumors and uses therefor
WO2014135655A1 (en) * 2013-03-06 2014-09-12 Institut Curie Compositions and methods for treating muscle-invasive bladder cancer
NZ630213A (en) * 2013-03-14 2017-05-26 Abraxis Bioscience Llc Methods of treating bladder cancer

Also Published As

Publication number Publication date
BR112017012553A2 (en) 2018-07-31
AU2015371312A1 (en) 2017-06-29
EP3237638B1 (en) 2020-01-15
EP3699290A1 (en) 2020-08-26
RU2017125053A (en) 2019-01-24
MX394474B (en) 2025-03-24
MX2017008421A (en) 2018-03-23
CN107223163A (en) 2017-09-29
US20230220491A1 (en) 2023-07-13
US20220267864A1 (en) 2022-08-25
AU2015371312B2 (en) 2022-01-27
KR20170095893A (en) 2017-08-23
IL252796A0 (en) 2017-08-31
RU2017125053A3 (en) 2019-07-17
JP2018508469A (en) 2018-03-29
SG11201704852SA (en) 2017-07-28
HK1244847A1 (en) 2018-08-17
WO2016105503A1 (en) 2016-06-30
EP3237638A1 (en) 2017-11-01
JP6900314B2 (en) 2021-07-07
JP2021169451A (en) 2021-10-28
CA2969830A1 (en) 2016-06-30
MY188938A (en) 2022-01-13
US20170306418A1 (en) 2017-10-26
RU2739942C2 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
IL252796B (en) Therapeutic, diagnostic and prognostic methods for bladder cancer
IL284172A (en) Diagnostic methods for T-cell therapy
IL296080B1 (en) Cancer treatment methods
IL271888A (en) Therapeutic and diagnostic methods for cancer
IL255312A0 (en) Therapeutic and diagnostic methods for cancer
IL261422A (en) Therapeutic and diagnostic methods for cancer
IL256025A (en) Methods for diagnosing and treating cancer
IL255261A0 (en) Cancer treatment methods
IL261468A (en) Uterine cancer treatments
IL255372A0 (en) Therapeutic and diagnostic methods for cancer
IL262208A (en) Diagnostic and therapeutic methods for cancer
HUE054012T2 (en) Combination therapy for cancer
GB201511152D0 (en) Method of diagnosing bladder cancer
HRP20190194T1 (en) 17A, 21-CORTEXOLONE DIETERS INTENDED FOR TUMOR TREATMENT
HUE037250T2 (en) Duokarmicin ADCs (Antibody Antibody Agents) For Use In Bladder Cancer Treatment
IL256139B (en) Methods for diagnosing bladder cancer
HUE038541T2 (en) Cancer Treatment Methods
SG11201701035SA (en) Cancer diagnosis and therapy
PT3134119T (en) CANCER TREATMENT
IL250692A0 (en) Medical treatments based on anamorelin
DK3389717T3 (en) NEOADJUVANT THERAPY FOR BLADDER CANCER
HUE046721T2 (en) Diagnostic method
DK3795130T3 (en) THERAPY APPARATUS.
GB201401806D0 (en) Novel methods for diagnosis and therapy
TH1501006324A (en) Cancer therapy with dihydropyrazine-pyrazine